Literature DB >> 25976199

Tocilizumab for refractory organising pneumonia associated with Sjögren's disease.

Aurelien Justet1, Sebastien Ottaviani2, Philippe Dieudé2, Camille Taillé1.   

Abstract

Lung involvement in primary Sjögren syndrome occurs in approximately 10-20% of patients. Tocilizumab, an anti-interleukin-6 receptor antibody, has demonstrated efficacy and safety in small series of systemic sclerosis, and systemic lupus erythematosus, but its effect on interstitial lung manifestations of connective tissue diseases is not well known. We report the use of tocilizumab in a refractory organising pneumonia associated with Sjögren's disease. Our observation suggests that tocilizumab could be an alternative therapeutic in refractory organising pneumonia. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25976199      PMCID： PMC4434320          DOI： 10.1136/bcr-2014-209076

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  18 in total

1.  Marked improvement of lung rheumatoid nodules after treatment with tocilizumab.

Authors:  Mariano Andres; Paloma Vela; Cintia Romera
Journal:  Rheumatology (Oxford)       Date:  2012-02-10       Impact factor: 7.580

2.  American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort.

Authors:  S C Shiboski; C H Shiboski; L A Criswell; A N Baer; S Challacombe; H Lanfranchi; M Schiødt; H Umehara; F Vivino; Y Zhao; Y Dong; D Greenspan; A M Heidenreich; P Helin; B Kirkham; K Kitagawa; G Larkin; M Li; T Lietman; J Lindegaard; N McNamara; K Sack; P Shirlaw; S Sugai; C Vollenweider; J Whitcher; A Wu; S Zhang; W Zhang; J S Greenspan; T E Daniels
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-04       Impact factor: 4.794

3.  Efficacy of tocilizumab for interstitial lung disease in an undifferentiated autoinflammatory disorder partially responsive to anakinra.

Authors:  Sarah M Keidel; Rachel K Hoyles; Nick M R Wilkinson
Journal:  Rheumatology (Oxford)       Date:  2013-08-22       Impact factor: 7.580

Review 4.  Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review.

Authors:  Andreas V Hadjinicolaou; Muhammad K Nisar; Shweta Bhagat; Helen Parfrey; Edwin R Chilvers; Andrew J K Ostör
Journal:  Rheumatology (Oxford)       Date:  2011-10-22       Impact factor: 7.580

5.  Exacerbation of combined pulmonary fibrosis and emphysema syndrome during tocilizumab therapy for rheumatoid arthritis.

Authors:  Daniel Wendling; Claire Vidon; Marie Godfrin-Valnet; Gilles Rival; Xavier Guillot; Clément Prati
Journal:  Joint Bone Spine       Date:  2013-04-23       Impact factor: 4.929

6.  A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab.

Authors:  Shin-Ya Kawashiri; Atsushi Kawakami; Noriho Sakamoto; Yuji Ishimatsu; Katsumi Eguchi
Journal:  Rheumatol Int       Date:  2010-05-18       Impact factor: 2.631

7.  A case of organizing pneumonia induced by tocilizumab.

Authors:  Kayoko Ikegawa; Masayuki Hanaoka; Atsuhito Ushiki; Hiroshi Yamamoto; Keishi Kubo
Journal:  Intern Med       Date:  2011-10-01       Impact factor: 1.271

8.  Neuromyelitis optica spectrum disorder complicated with Sjogren syndrome successfully treated with tocilizumab: A case report.

Authors:  Toshihiko Komai; Hirofumi Shoda; Kenichi Yamaguchi; Keiichi Sakurai; Mihoko Shibuya; Kanae Kubo; Toshiyuki Takahashi; Keishi Fujio; Kazuhiko Yamamoto
Journal:  Mod Rheumatol       Date:  2013-12-09       Impact factor: 3.023

9.  Organising pneumonia can be the inaugural manifestation in connective tissue diseases, including Sjogren's syndrome.

Authors:  A C Henriet; E Diot; S Marchand-Adam; A de Muret; O Favelle; B Crestani; P Diot
Journal:  Eur Respir Rev       Date:  2010-06

10.  Respiratory reovirus 1/L induction of intraluminal fibrosis, a model of bronchiolitis obliterans organizing pneumonia, is dependent on T lymphocytes.

Authors:  Elizabeth I Majeski; Manjeet K Paintlia; Andrea D Lopez; Russell A Harley; Steven D London; Lucille London
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307
View more
  7 in total

Review 1.  Treatment of primary Sjögren syndrome.

Authors:  Alain Saraux; Jacques-Olivier Pers; Valérie Devauchelle-Pensec
Journal:  Nat Rev Rheumatol       Date:  2016-07-14       Impact factor: 20.543

Review 2.  The Two-Faced Cytokine IL-6 in Host Defense and Diseases.

Authors:  Masashi Narazaki; Tadamitsu Kishimoto
Journal:  Int J Mol Sci       Date:  2018-11-09       Impact factor: 5.923

Review 3.  Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review.

Authors:  Caterina Vacchi; Marco Sebastiani; Giulia Cassone; Stefania Cerri; Giovanni Della Casa; Carlo Salvarani; Andreina Manfredi
Journal:  J Clin Med       Date:  2020-02-03       Impact factor: 4.241

Review 4.  Innate Immunity and Biological Therapies for the Treatment of Sjögren's Syndrome.

Authors:  Amrita Srivastava; Helen P Makarenkova
Journal:  Int J Mol Sci       Date:  2020-12-01       Impact factor: 5.923

5.  Composition and regulation of the immune microenvironment of salivary gland in Sjögren's syndrome.

Authors:  Zhen Tan; Li Wang; Xiaomei Li
Journal:  Front Immunol       Date:  2022-09-13       Impact factor: 8.786

Review 6.  Shared Pathogenetic Features Between Common Variable Immunodeficiency and Sjögren's Syndrome: Clues for a Personalized Medicine.

Authors:  Luca Quartuccio; Ginevra De Marchi; Simone Longhino; Valeria Manfrè; Maria Teresa Rizzo; Saviana Gandolfo; Alberto Tommasini; Salvatore De Vita; Robert Fox
Journal:  Front Immunol       Date:  2021-07-12       Impact factor: 7.561

Review 7.  Biological Therapy in Primary Sjögren's Syndrome: Effect on Salivary Gland Function and Inflammation.

Authors:  Farzana Chowdhury; Anwar Tappuni; Michele Bombardieri
Journal:  Front Med (Lausanne)       Date:  2021-07-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.